JAACAP open最新文献

{"title":"Review: Evidence-Based Psychosocial Treatments for Childhood Irritability and Aggressive Behavior","authors":"Carla B. Kalvin PhD,&nbsp;Julia Zhong BS,&nbsp;Megan R. Rutten BS,&nbsp;Karim Ibrahim PsyD,&nbsp;Denis G. Sukhodolsky PhD","doi":"10.1016/j.jaacop.2024.01.009","DOIUrl":"10.1016/j.jaacop.2024.01.009","url":null,"abstract":"<div><h3>Objective</h3><div>Irritability and aggression are among the most common reasons that children are referred to outpatient mental health services and represent symptoms of several child psychiatric disorders. Over the past 40 years, several types of psychosocial interventions have been developed to treat these problems. This review examines well-established interventions for childhood irritability and aggression as well as newer interventions with a growing evidence base.</div></div><div><h3>Method</h3><div>This is a narrative review of evidence-based psychosocial treatments for childhood irritability and maladaptive aggression highlighting the key principles, techniques, and assessment tools as relevant to clinical practice.</div></div><div><h3>Results</h3><div>Parent management training and cognitive-behavioral therapy both have extensive evidence bases and are recognized as efficacious interventions for childhood aggression and disruptive behavior. There is also accumulating evidence that these modalities as well as dialectical behavior therapy can be helpful for irritability in the context of severe mood dysregulation and disruptive mood dysregulation disorder. Technology-based and telehealth interventions for childhood aggression and irritability show promising results and potential to improve access to services. Lastly, measurement-based care, while still a developing area in child mental health, may provide a promising addition to enhancing the efficacy and precision of psychosocial treatments of childhood aggression and irritability.</div></div><div><h3>Conclusion</h3><div>Parent- and child-focused psychosocial interventions such as parent management training, cognitive-behavioral therapy, and their combination can be helpful for the reduction of irritability and aggression. Well-powered randomized controlled trials with outcome measures that reflect current conceptualization of maladaptive aggression and irritability are needed to extend this evidence base to older adolescents and to examine the role of co-occurring psychopathology in treatment response.</div></div><div><h3>Plain language summary</h3><div>Childhood irritability, excessive anger, and aggressive behavior are among the most common reasons that children are referred to mental health services. This narrative review discusses psychosocial interventions that have been shown to improve these emotional and behavioral symptoms through rigorous clinical research. In addition to a practical discussion of psychotherapeutic techniques for working with children presenting with irritability and aggressive behavior, the authors review innovative approaches and identify areas for future research.</div></div>","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"3 1","pages":"Pages 14-28"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered Neural Activation in First Episode Psychosis Patients With Comorbid Conduct Disorder: A Pilot Investigation","authors":"Nathan J. Kolla MD, PhD, FRCPC ,&nbsp;Ryan Aloysius BSc ,&nbsp;George Gainham BSc ,&nbsp;Colin Hawco PhD","doi":"10.1016/j.jaacop.2024.04.001","DOIUrl":"10.1016/j.jaacop.2024.04.001","url":null,"abstract":"<div><h3>Objective</h3><div>Most individuals with psychosis do not perpetrate violence. However, conduct disorder (CD) increases the risk of violence in psychotic conditions. Because it is currently unknown whether the neural correlates of first-episode psychosis (FEP) differ when CD is present, we used functional magnetic resonance imaging (fMRI) during a Go/No-Go impulsivity paradigm to investigate. Based on previous research, we hypothesized that activation differences between FEP and FEP+CD would be found in the prefrontal cortex, cingulate cortex, and inferior parietal lobule.</div></div><div><h3>Method</h3><div>We scanned 51 male participants: 17 FEP, 16 FEP+CD, and 18 healthy controls with an average age of 24.2 years (range, 17-34 years). Whole-brain images were analyzed via a general linear model, and first-level contrast images were created comparing successful No-Go &gt; Go trials. Paired <em>t</em> tests were conducted at the group level and included confound regressors for age, IQ, antipsychotic dose, psychotic symptoms, and framewise displacement. A voxel-based <em>Z</em>-score threshold of Z &gt; 3.1 (<em>p</em> &lt; 0.001, uncorrected) and a cluster-level extent threshold of <em>p</em> &lt;0.01, corrected, was considered significant.</div></div><div><h3>Results</h3><div>Successful response inhibition elicited hyperactivation in FEP+CD vs FEP in the cingulate gyrus; regions of the PFC, including right middle frontal gyrus (RMFG); bilateral inferior parietal lobule; temporal gyrus; and cerebellum (<em>p</em> values ranged from 1.11E-08 to 0.0031). There was no region in which activation was greater in FEP &gt; FEP+CD.</div></div><div><h3>Conclusion</h3><div>These preliminary results tentatively suggest that brain regions subserving response inhibition may be altered when CD is comorbid with FEP.</div></div><div><h3>Plain language summary</h3><div>Conduct disorder increases the risk of aggression among individuals with psychosis. This study used fMRI during a task measuring impulsivity to determine whether individuals with first episode psychosis and comorbid conduct disorder have different brain responses than individuals with first episode psychosis alone and healthy controls. Increased activation of the prefrontal cortex, cingulate gyrus, bilateral inferior parietal lobule, temporal gyrus and cerebellum was found in first episode psychosis with conduct disorder versus first episode psychosis alone. These preliminary results suggest that brain regions subserving response inhibition may be altered when conduct disorder is comorbid with first episode psychosis.</div></div>","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"3 1","pages":"Pages 101-113"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scope","authors":"","doi":"10.1016/S2949-7329(25)00018-3","DOIUrl":"10.1016/S2949-7329(25)00018-3","url":null,"abstract":"","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"3 1","pages":"Page A1"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review: Dopamine, Serotonin, and the Translational Neuroscience of Aggression in Autism Spectrum Disorder","authors":"Hugo Martin PhD,&nbsp;Ja Eun Choi PhD,&nbsp;Ariana R. Rodrigues BA candidate,&nbsp;Neir Eshel MD, PhD","doi":"10.1016/j.jaacop.2024.01.010","DOIUrl":"10.1016/j.jaacop.2024.01.010","url":null,"abstract":"<div><h3>Objective</h3><div>Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a 1% to 2% prevalence in children. In addition to social communication deficits and restricted or repetitive behavior, ASD is often characterized by a heightened propensity for aggression. In fact, aggressive behavior is the primary reason for hospitalization in children with ASD, and current treatment options, despite some efficacy, are often associated with prominent side effects. Despite such high clinical toll, the neurobiology of aggression in ASD remains poorly understood.</div></div><div><h3>Method</h3><div>The neural circuits linked to both ASD and aggression were reviewed, with the goal of identifying overlapping components to help guide future treatment development. In discussing the clinical phenotype of aggression in ASD, some of the triggers and risk factors were noted to differ from those that cause aggression in neurotypical children. Preclinical and clinical studies on the neurobiology of aggression and ASD were synthesized to combine evidence from genetics, neuroimaging, pharmacology, and circuit manipulations. Dopamine and serotonin, 2 neuromodulators that contribute to development and behavioral control, were specifically studied.</div></div><div><h3>Results</h3><div>The literature indicates that the intricate interplay of the dopamine and serotonin systems has a pivotal role in shaping behavior, including the expression of aggression.</div></div><div><h3>Conclusion</h3><div>Understanding the balance between dopamine as an accelerator and serotonin as a brake may provide insights into the mechanisms of aggression in children with ASD. Although much work remains to be done, new perspectives promise to bridge the gap between human and animal studies and pinpoint the neurobiology of aggression in ASD.</div></div><div><h3>Plain language summary</h3><div>This narrative review explores how serotonin and dopamine might contribute to the presentation of aggression in individuals with autism spectrum disorder. Synthesizing animal and human studies, the review suggests that diminished serotonin levels may contribute to aggression in response to social threats while increased dopamine levels might facilitate aggression in response to the disruption of routines.</div></div><div><h3>Diversity &amp; Inclusion Statement</h3><div>One or more of the authors of this paper self-identifies as a member of one or more historically underrepresented sexual and/or gender groups in science. We actively worked to promote sex and gender balance in our author group.</div></div>","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"3 1","pages":"Pages 29-41"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Double-Blind, Placebo-Controlled Study of Adjunctive Topiramate in Adolescents With Co-Occurring Bipolar and Cannabis Use Disorders","authors":"Jenni E. Farrow MD,&nbsp;Melissa P. DelBello MD, MS,&nbsp;Luis R. Patino MD, MSc,&nbsp;Thomas J. Blom MS,&nbsp;Jeffrey A. Welge PhD","doi":"10.1016/j.jaacop.2024.08.002","DOIUrl":"10.1016/j.jaacop.2024.08.002","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To evaluate the efficacy of adjunctive topiramate (TPM) for the treatment of cannabis use disorder in adolescents with bipolar I disorder.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Method&lt;/h3&gt;&lt;div&gt;We conducted a 16-week, double-blind, randomized, placebo-controlled investigation of quetiapine plus TPM (median dose = 208 mg) vs quetiapine plus placebo in adolescents with bipolar I and cannabis use disorder. All subjects participated in a Motivational Interview and Compliance Enhancement Therapy. The primary outcome measure was change in weekly cannabis use over a 16-week treatment period using the Timeline Followback. The secondary outcome measure was the baseline-to-endpoint total score change in the Young Mania Rating Scale (YMRS).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 75 participants completed at least 1 post-baseline assessment (TPM = 38, placebo = 37). There was a significant time-by-treatment effect over the 16-week treatment period, with baseline-adjusted treatment differences in favor of the TPM group over time (&lt;em&gt;p&lt;/em&gt; &lt; .001). Although there was no difference in baseline-to-endpoint YMRS total score change between groups (&lt;em&gt;p&lt;/em&gt; = .342), there was a&lt;del&gt;s&lt;/del&gt; significant decline in YMRS total score within both groups (&lt;em&gt;p&lt;/em&gt; &lt; .0001). There was a significant positive effect for alcohol use (&lt;em&gt;p&lt;/em&gt; &lt; .001) and nicotine use (&lt;em&gt;p&lt;/em&gt; = .033) in the TPM group. More participants in the TPM group experienced appetite decrease (&lt;em&gt;p&lt;/em&gt; = .032) and excitement (&lt;em&gt;p&lt;/em&gt; = .025). Participants in the placebo group experienced greater weight gain (&lt;em&gt;p&lt;/em&gt; = .010).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Treatment with TPM adjunctive to quetiapine and a Motivational Interview and Compliance Enhancement Therapy is associated with a greater decrease in cannabis use and less weight gain. TPM is a well-tolerated and efficacious treatment for cannabis use disorder in adolescents with bipolar I disorder.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain language summary&lt;/h3&gt;&lt;div&gt;Cannabis is the most commonly misused drug in adolescents with bipolar disorder, and there is limited prior research supporting the addition of topiramate to motivational enhancement for the treatment of cannabis use disorder. In this study, 75 adolescents and young adults, aged 12-21, with bipolar I disorder participated in a 16-week, double-blind, randomized, placebo-controlled trial of quetiapine plus topiramate versus quetiapine plus placebo treatment for cannabis use disorder. All subjects participated in a Motivational Interview and Compliance Enhancement Therapy. The group receiving topiramate had a greater decrease in the use of cannabis, alcohol, and nicotine, as well as less weight gain. These results suggest that adjunctive topiramate to quetiapine and motivational interview may be helpful in the treatment of cannabis use disorder in adolescents and young adults with bipolar 1 disorder.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Clinical trial registration informat","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"2 4","pages":"Pages 290-300"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medications for Opioid Use Disorder Among Transition Age Youth Compared to Adults 26 or Older in Rural Settings","authors":"José M. Flores MD, PhD ,&nbsp;Emily Kan PhD ,&nbsp;Larissa J. Mooney MD ,&nbsp;Huyen Pham PhD ,&nbsp;Yuhui Zhu PhD ,&nbsp;Kate Wolitzky-Taylor PhD ,&nbsp;Yih-Ing Hser PhD","doi":"10.1016/j.jaacop.2024.02.001","DOIUrl":"10.1016/j.jaacop.2024.02.001","url":null,"abstract":"<div><h3>Objective</h3><div>Transition age youth (TAY), aged 18 to 25 years, face barriers to medication treatment for opioid use disorder (MOUD), resulting in lower retention. We evaluated OUD prevalence and MOUD receipt comparing TAY to adults aged 26 or older residing in rural settings.</div></div><div><h3>Method</h3><div>Electronic health records (October 2019 to January 2021) for 36,762 patients across 6 primary care clinics involved in a large feasibility trial in US rural communities were analyzed. All clinics implemented a standardized intervention. Mixed effects logistic/linear regression estimated the odds of OUD diagnosis among all patients, and, among those with OUD, the odds of receiving MOUD and days prescribed MOUD during the 15-month study period, comparing age categories (TAY aged 18-25 years vs adults 26 years or older). Covariates included gender, race, ethnicity, mental health comorbidities, and insurance status.</div></div><div><h3>Results</h3><div>OUD prevalence was 2.82% among TAY (n = 3,122) and 3.24% among adults aged 26 or older (n = 33,208). After adjusting for covariates and clustering, TAY had significantly lower odds of OUD diagnosis compared to adults 26 years or older (odds ratio = 0.58, 95% CI 0.45-0.73). There were no significant differences in MOUD receipt between age groups. Compared to adults aged 26 or older, TAY with OUD had significantly fewer MOUD days during the study, −43.81 days (−76.85 to −10.77).</div></div><div><h3>Conclusion</h3><div>Although no differences were observed in MOUD prescription receipt between TAY and adults aged 26 or older, TAY with OUD had fewer total days prescribed MOUD, indicating lower retention. Further research generalizable to rural communities is needed to assess retention among rural TAY with OUD.</div></div><div><h3>Plain language summary</h3><div>This study used data from the electronic health records of 6 rural primary care clinics across three states to compare the diagnostic rates of opioid use disorder (OUD) and the prescription of medications for opioid use disorder (MOUD) between 3,122 transition age youths (aged 18-25) and 33,208 adults aged 26 or older. The study found that the rates of OUD were lower in youths under age 25 compared to adults 26 or older. However, among participants diagnosed with OUD, youths under age 25 received 43 to 63 fewer days of prescribed MOUD compared to adults 26 years or older. These findings indicate possible inconsistencies in care such as lower retention or lower adherence affecting transition age youths compared to adults 26 or older. These findings highlight the need for age-appropriate interventions to improve treatment among youths with opioid use disorder in rural settings.</div></div><div><h3>Clinical trial registration information</h3><div>Rural MOUD Telemedicine in Primary Care Phase 1 (Feasibility); <span><span>https://clinicaltrials.gov/</span><svg><path></path></svg></span>; NCT04418453.</div></div>","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"2 4","pages":"Pages 231-238"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Association Between Prenatal Cannabis Use and Risk of Developmental Delay","authors":"Dana Watts MSc ,&nbsp;Catherine Lebel PhD ,&nbsp;Kathleen Chaput PhD ,&nbsp;Gerald F. Giesbrecht PhD, RPsych ,&nbsp;Kyle Dewsnap MA ,&nbsp;Samantha L. Baglot MSc ,&nbsp;Lianne Tomfohr-Madsen PhD","doi":"10.1016/j.jaacop.2024.03.004","DOIUrl":"10.1016/j.jaacop.2024.03.004","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;Conflicting results have arisen regarding the association between prenatal cannabis exposure and risk of parent-reported developmental delay in infancy. In certain instances, this literature has become outdated or failed to adjust for confounding variables. The current study aimed to determine if prenatal cannabis exposure was associated with a greater likelihood of risk of parent-reported developmental delay at 12 months of age in a contemporary cohort, while adjusting for common confounding variables.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Method&lt;/h3&gt;&lt;div&gt;Participants (n = 10,695) were part of the Pregnancy During the COVID-19 Pandemic (PdP) study. A subset of the sample (n = 3,742) provided a parent-report developmental assessment, the Ages and Stages Questionnaire, Third Edition (ASQ-3), of their infant at 12 months old. Sociodemographic differences between participants who reported cannabis use (CU+ group) and those who did not (CU− group) were analyzed. To address potential heterogeneity between CU+ and CU− groups, propensity score weighting was used. G-computations were performed to analyze the association between outcome variables (gestational age, birth weight, and risk of parent-reported developmental delay) and prenatal cannabis exposure. Weighted linear or quasi-binominal logistic regression models were used, with differences of averages and odds ratios reported.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Participants in CU+ and CU− groups significantly differed on all sociodemographic variables. Prenatal cannabis exposure was not associated with any birth outcomes (&lt;em&gt;p&lt;/em&gt;s &gt; .05). Prenatal cannabis exposure was significantly associated with risk of parent-reported developmental delay on the communication domain (&lt;em&gt;p&lt;/em&gt; = .02). This finding was not significant after adjusting for multiple comparisons. No additional domains were significantly associated (&lt;em&gt;p&lt;/em&gt;s &gt; .05).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Prenatal cannabis exposure was associated with increased odds of delay on the communication domain before adjusting for multiple comparisons. No other domains were significantly associated with increased odds of delay. These findings should not be interpreted as suggesting that consuming cannabis products during pregnancy is safe for infant development. Further, the analysis was performed using data from a longitudinal sample that was not specifically created to address this question, but was leveraged to explore these outcomes. Additional studies that are specifically designed to examine these outcomes are needed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain language summary&lt;/h3&gt;&lt;div&gt;Prior research has been conflicting regarding the link between prenatal cannabis exposure and developmental delays. Secondary analysis of data from the cross-Canada Pregnancy During the COVID-19 Pandemic (PdP) study showed significant sociodemographic differences between individuals who did and did not use cannabis during pregnancy. However, prenat","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"2 4","pages":"Pages 250-262"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Monitoring Illicit Substance Use Consortium: A Study Protocol","authors":"Christopher J. Greenwood BPsych(Hons), PhD ,&nbsp;Primrose Letcher MPsych(Clin), PhD ,&nbsp;Esther Laurance BA, MCrim ,&nbsp;Joseph M. Boden PhD ,&nbsp;James Foulds PhD ,&nbsp;Elizabeth A. Spry BA(Hons), PhD ,&nbsp;Jessica A. Kerr PhD ,&nbsp;John W. Toumbourou BA(Hons), MA, PhD ,&nbsp;Jessica A. Heerde PhD ,&nbsp;Catherine Nolan GradDipAppHlth ,&nbsp;Yvonne Bonomo MBBS, FRACP, PhD, FAChAM ,&nbsp;Delyse M. Hutchinson MClinPsych, PhD ,&nbsp;Tim Slade PhD ,&nbsp;Stephanie R. Aarsman MBiostat ,&nbsp;Craig A. Olsson PhD","doi":"10.1016/j.jaacop.2024.03.002","DOIUrl":"10.1016/j.jaacop.2024.03.002","url":null,"abstract":"<div><h3>Objective</h3><div>The global impact of substance use, including cannabis, amphetamine, cocaine, ecstasy, hallucinogens, and opioids, is increasing, although the overall prevalence is low. Australia and New Zealand are among the few regions of the world in which use (typically illicit) of these classes of substances remains within the top 10 causes of disease burden. The period of adolescence and young adulthood, during which substance use behaviors accelerate in prevalence, is associated with a particular risk for harm. However, the ability to study each substance class has been limited by their low population prevalence in single population-based cohort studies.</div></div><div><h3>Method</h3><div>The Monitoring Illicit Substance Use (MISUse) Consortium was established to address this problem by bringing together 4 mature prospective cohort studies across Australia and Zealand: Christchurch Health and Development Study (established 1977; 24 waves; N = 1,265), Australian Temperament Project (established 1983; 16 waves; N = 2,443), Victorian Adolescent Health Cohort Study (established 1992; 11 waves; N = 1,943), and International Youth Development Study (established 2002; 10 waves; N = 2,884).</div></div><div><h3>Conclusion</h3><div>The MISUse Consortium should enable well-powered studies of the natural history, developmental antecedents, and longer-term consequences of illicit substance use with a focus on identifying modifiable determinants of use that can be targeted in population-level policy and intervention responses.</div></div><div><h3>Plain language summary</h3><div>Illicit substance use is a leading risk factor for disease burden in Australasia. However, the low prevalence of use limits research efforts. The MISUse Consortium brings together four mature Australasian cohort studies, from adolescence to adulthood, building a harmonized data resource capable of examining the natural history, developmental origins, and consequences of illicit substance use.</div></div>","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"2 4","pages":"Pages 311-322"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis Vaping Is Associated With Past 30-Day Suicide Attempts and Suicidal Ideation Among Adolescents in a Psychiatric Inpatient Setting","authors":"Sarah A. Thomas PhD ,&nbsp;Elizabeth C. Thompson PhD ,&nbsp;Micaela M. Maron BS ,&nbsp;Samuel N. Meisel PhD ,&nbsp;Anthony Spirito PhD ,&nbsp;Jennifer C. Wolff PhD","doi":"10.1016/j.jaacop.2024.03.003","DOIUrl":"10.1016/j.jaacop.2024.03.003","url":null,"abstract":"<div><h3>Objective</h3><div>Increasing evidence links adolescent cannabis use (CU) to suicidal thoughts and behaviors. CU may be associated with both developing and self-medicating psychiatric symptoms. Although relatively new, cannabis vaping is increasing among adolescents. This chart review investigation evaluated the association between cannabis vaping and suicidal thoughts and behaviors among adolescents experiencing acute psychiatric symptomatology.</div></div><div><h3>Method</h3><div>The sample included 470 adolescents (ages 11-18; 64% biological female) admitted to an inpatient psychiatric hospital between 2021 and 2023. Adolescents completed an assessment battery measuring CU, psychiatric symptoms, and suicidal thoughts and behaviors. Separate regressions tested links between cannabis vaping and 2 outcomes—past 30-day suicide attempt and suicidal ideation (SI)—controlling for age and biological sex.</div></div><div><h3>Results</h3><div>In this sample, 26.8% reported past 30-day suicide attempts; 44.3% endorsed ever using cannabis, and 31.5% reported past 30-day CU. Of adolescents who ever used cannabis, 30.8% reported their most frequent method was vaping. Vaping as the most frequent cannabis method was associated with past 30-day suicide attempts (adjusted odds ratio = 2.38, <em>p</em> = .002) and greater SI (<em>b</em> = 8.71, <em>p</em> = .020). The association remained significant for suicide attempts, but only marginally significant for SI (<em>p</em> = .087), after controlling for depressive symptoms, impulse control, psychosocial impairment, and past 30-day substance use.</div></div><div><h3>Conclusion</h3><div>Vaping as the most frequent method of CU was significantly associated with suicide attempts and SI. Because data are cross-sectional, causality cannot be inferred. Nonetheless, cannabis vaping is important to assess among adolescents with acute psychiatric concerns because it may place them at higher risk for suicidal thoughts and attempts.</div></div><div><h3>Plain language summary</h3><div>Vaping can deliver higher potency cannabis than other routes of administration, and adolescents are increasingly vaping to consume cannabis. This chart review study of 470 adolescents admitted to an inpatient psychiatric hospital found that vaping is the most frequent way of using cannabis. Vaping was associated with a greater likelihood of a past 30-day suicide attempt and worse suicidal thoughts compared to adolescents who never used or who smoked cannabis as their primary method. Adults should be aware of how adolescents are consuming cannabis, especially if it is occurring in the context of psychiatric disorders.</div></div>","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"2 4","pages":"Pages 263-273"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141038513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invisible Allies: Thanking Our Reviewers","authors":"","doi":"10.1016/j.jaacop.2024.10.002","DOIUrl":"10.1016/j.jaacop.2024.10.002","url":null,"abstract":"","PeriodicalId":73525,"journal":{"name":"JAACAP open","volume":"2 4","pages":"Pages 323-325"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}